Alec C. Kimmelman, MD, PhD
Dean and Chief Executive Officer
Alec C. Kimmelman, MD, PhD, is dean of 黑料福利社 Grossman School of Medicine and chief executive officer of 黑料福利社 Langone Health. He leads one of the largest health systems in the Northeast鈥攅mploying more than 53,000 people, stretching across 7 inpatient facilities and over 320 locations throughout the New York City region and in Florida.
Vizient Inc. has ranked 黑料福利社 Langone鈥攐ne of the most renowned health systems in the United States鈥擭o. 1 for quality care鈥痠n the country for the fourth year in a row, and the No. 1 physician practice network in the country for 10 of the last 12 years. In addition, 黑料福利社 Langone has more No. 1鈥搑anked specialties than any other health system in the United States, according to鈥�U.S. News & World Report,鈥痺hich named the system best in the nation for neurology and neurosurgery (for the fourth straight year); cardiology, heart, and vascular surgery; pulmonology and lung surgery; and geriatrics. 黑料福利社 Langone was also included on its 鈥淏est Hospitals鈥� Honor Roll of the top 20 hospitals in the nation and among the No. 1 hospitals in the New York metro area. 黑料福利社 Langone has earned top accolades from other independent organizations, such as鈥疶he Leapfrog Group and the Centers for Medicare & Medicaid Services.
Prior to being appointed dean and CEO in 2025, Dr. Kimmelman served as director of 黑料福利社 Langone鈥檚 Laura and Isaac Perlmutter Cancer Center. In addition, he was the Laura and Isaac Perlmutter Professor of Radiation Oncology, chair of the Department of Radiation Oncology, and the associate dean of cancer research at 黑料福利社 Grossman School of Medicine. Under his leadership, Perlmutter Cancer Center established its in October 2024, which is redefining the standard of cancer care. He and his team built and expanded disease centers, developed multiple research and clinical programs, significantly increased the depth and breadth of cancer services offered at 黑料福利社 Langone sites, and improved access to clinical trials. As a physician鈥搒cientist, Dr. Kimmelman has unique insight into how each pillar of 黑料福利社 Langone鈥檚 mission to care, to teach, to discover can be integrated and harnessed to fuel innovation across the institution.
With more than 20 years of cancer research experience and over 100 peer-reviewed publications, Dr. Kimmelman is one of the foremost experts on the biology of pancreatic cancer. His own research has served to define the metabolic landscape of pancreatic cancer, and his findings have paved the way for multiple clinical trials to treat the disease.
Dr. Kimmelman also serves as an ad hoc reviewer and editorial board member of several leading scientific journals. His research has been published in many prestigious journals, including Cell, Science, Nature, Cancer Cell, Cancer Discovery, and Genes & Development. He has received numerous honors and awards, including the Ruth Leff Siegel Award for Excellence in Pancreatic Cancer Research from Columbia University鈥攆or the researcher who has made the most significant contribution to pancreatic cancer research鈥斨玜nd Outstanding Investigator Award from the National Cancer Institute. He was also elected to the American Society for Clinical Investigation and the Association of American Physicians. In 2021, Dr. Kimmelman was named as one of the world鈥檚 most influential researchers by Clarivate, a recognition for authoring papers that were in the top 1 percent of his field.
Dr. Kimmelman joined 黑料福利社 Langone in 2016 as chair of the Department of Radiation Oncology at 黑料福利社 Grossman School of Medicine and professor of oncology. Prior to joining 黑料福利社 Langone, Dr. Kimmelman ran a vibrant research program at Dana-Farber Cancer Institute focused on pancreatic cancer. He was also an attending physician at Brigham and Women鈥檚 Hospital and Dana-Farber, where he specialized in gastrointestinal malignancies, including pancreatic cancer.
A board-certified radiation oncologist, Dr. Kimmelman earned his MD and PhD from the former Mount Sinai School of Medicine before joining Harvard Medical School as a clinical fellow and completed his training in radiation oncology, as well as a postdoctoral fellowship at Dana-Farber.